痛风患者未达血尿酸<0.36 mmol/L目标与全因及心血管死亡升高相关
该前瞻性队列纳入1992—2017年就诊的1193例痛风患者,以随访第一年平均血尿酸(sUA)≤或>0.36 mmol/L分组,用Cox模型分析死亡风险。随访平均48个月、158例死亡;校正年龄、性别、心血管危险因素、既往心血管事件、观察期和基线sUA后,sUA≥0.36 mmol/L与全因死亡(HR=2.33,95%CI 1.60–3.41)和心血管死亡(HR=2.05,95%CI 1.21–3.45)升高相关。作者结论:未达sUA<0.36 mmol/L目标是全因和心血管死亡的独立预测因素,应作为该类高危患者的主要治疗目标。
要点
- 痛风患者随访第一年平均sUA≥0.36 mmol/L者全因死亡风险升高(HR=2.33)。
- sUA≥0.36 mmol/L者心血管死亡风险亦升高(HR=2.05)。
- 将sUA控制在<0.36 mmol/L应作为痛风高危患者的主要目标。
核心结论
- 在痛风高尿酸血症患者中,未达到sUA<0.36 mmol/L目标是全因死亡和心血管死亡的独立预测因素。
研究设计与样本
- 前瞻性队列研究,纳入1992—2017年招募的1193例痛风患者,暴露为随访第一年平均sUA,按≤或>0.36 mmol/L二分,采用双变量和多变量Cox比例风险模型评估死亡风险。
主要发现
- 1193例患者中92%为男性,平均年龄60岁,平均病程6.8年,前一年平均发作3–4次,基线平均sUA 9.1 mg/dL,平均随访48个月,158例死亡。
- sUA≥0.36 mmol/L组粗死亡率80.9/1000人年(95%CI 59.4–110.3),高于sUA<0.36 mmol/L组的25.7/1000人年(95%CI 21.3–30.9)。
- 校正年龄、性别、心血管危险因素、既往心血管事件、观察期和基线sUA后,sUA≥0.36 mmol/L与全因死亡升高相关(HR=2.33,95%CI 1.60–3.41)。
- 校正后sUA≥0.36 mmol/L与心血管死亡升高相关(HR=2.05,95%CI 1.21–3.45)。
关键数值与推荐
- 目标sUA水平为<0.36 mmol/L。
- sUA≥0.36 mmol/L组粗死亡率为80.9/1000人年(95%CI 59.4–110.3)。
- sUA<0.36 mmol/L组粗死亡率为25.7/1000人年(95%CI 21.3–30.9)。
临床怎么用
- 对痛风合并高尿酸血症的高危患者,应以sUA<0.36 mmol/L作为主要治疗目标,以降低心血管事件并延长生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the impact of achieving serum uric acid (sUA) of <0.36 mmol/L on overall and cardiovascular (CV) mortality in patients with gout. METHODS: Prospective cohort of patients with gout recruited from 1992 to 2017. Exposure was defined as the average sUA recorded during the first year of follow-up, dichotomised as ≤ or >0.36 mmol/L. Bivariate and multivariate Cox proportional hazards models were used to determine mortality risks, expressed HRs and 95% CIs. RESULTS: Of 1193 patients, 92% were men with a mean age of 60 years, 6.8 years' disease duration, an average of three to four flares in the previous year, a mean sUA of 9.1 mg/dL at baseline and a mean follow-up 48 months; and 158 died. Crude mortality rates were significantly higher for an sUA of ≥0.36 mmol/L, 80.9 per 1000 patient-years (95% CI 59.4 to 110.3), than for an sUA of <0.36 mmol/L, 25.7 per 1000 patient-years (95% CI 21.3 to 30.9). After adjustment for age, sex, CV risk factors, previous CV events, observation period and baseline sUA concentration, an sUA of ≥0.36 mmol/L was associated with elevated overall mortality (HR=2.33, 95% CI 1.60 to 3.41) and CV mortality (HR=2.05, 95% CI 1.21 to 3.45). CONCLUSIONS: Failure to reach a target sUA level of 0.36 mmol/L in patients with hyperuricaemia of gout is an independent predictor of overall and CV-related mortality. Targeting sUA levels of <0.36 mmol/L should be a principal goal in these high-risk patients in order to reduce CV events and to extend patient survival.
引用
- Pérez Ruiz F, Richette P, Stack AG, et al. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019. PMID: 31673414. doi:10.1136/rmdopen-2019-001015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。